If you’ve been researching medical weight loss, you’ve almost certainly come across two names: semaglutide and tirzepatide. Sold under brand names like Ozempic, Wegovy, Mounjaro, and Zepbound, these medications have transformed the weight loss landscape over the past several years — and patients in Little Rock are asking about them every day.
But what’s actually the difference? And how does a provider decide which one is right for a particular patient? Here’s a straightforward explanation.
What Is Semaglutide?
Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It works by mimicking a hormone your body naturally produces after eating — one that signals fullness, slows the rate at which food leaves your stomach, and reduces appetite. It also has meaningful effects on blood sugar regulation, which is why it was originally developed for type 2 diabetes (Ozempic) before a higher-dose formulation was approved specifically for weight loss (Wegovy).
In clinical trials, patients on semaglutide lost an average of 15% of their body weight over 68 weeks. For many patients, this represents more weight loss than any previous intervention they had tried.
What Is Tirzepatide?
Tirzepatide is a dual agonist — meaning it activates two receptors rather than one. In addition to the GLP-1 receptor that semaglutide targets, tirzepatide also activates the GIP (glucose-dependent insulinotropic polypeptide) receptor. This dual action appears to amplify both the metabolic and appetite-suppressing effects of the medication.
In clinical trials, tirzepatide produced even more significant weight loss than semaglutide — averaging around 20–22% of body weight in some studies. It has been approved for weight loss under the brand name Zepbound, and for diabetes management as Mounjaro.
So Which One Is Better?
On a purely clinical basis, tirzepatide has demonstrated stronger average weight loss outcomes in head-to-head comparisons. However, ‘better’ in medicine is always patient-specific.
Factors that influence the decision include your current medications and whether there are any interactions to consider, your insurance coverage (availability and cost differ significantly between the two), your history with either medication if you’ve tried one before, the presence of type 2 diabetes or prediabetes, and how your body responds to each medication’s side effect profile.
Some patients do exceptionally well on semaglutide. Others respond better to tirzepatide. And some patients try one and switch to the other. The right answer requires a real medical conversation — not a quiz on a telehealth app.
What About Side Effects?
Both medications share a similar side effect profile, primarily gastrointestinal: nausea, constipation, and occasional vomiting, particularly when starting or increasing doses. These effects are typically most pronounced in the first few weeks and improve as the body adjusts.
Starting at a low dose and titrating slowly — which is standard practice at The Batson Clinic — significantly reduces the likelihood and severity of these side effects.
The Importance of Medical Supervision
Neither semaglutide nor tirzepatide should be started without a thorough medical evaluation. These medications interact with other drugs, are contraindicated in certain conditions (including a personal or family history of medullary thyroid cancer), and require ongoing monitoring to be used safely and effectively.
At The Batson Clinic in Little Rock, every GLP-1 patient receives a full health assessment and lab work before starting, regular check-ins during the program, and provider access when questions come up. Because Katherine is also your primary care provider, your weight loss treatment is fully integrated with your overall health — not siloed in a separate clinic.
Ready to Learn More?
We’re currently accepting new weight loss patients at The Batson Clinic, with same-week appointments available.
Call (501) 406-3933 or visit batsonhealth.com to schedule a consultation. We’ll help you figure out which approach is right for your specific health history and goals.